Advances and perspectives in the development of vaccines against highly pathogenic bunyaviruses

Tong Chen; Zhe Ding; Jiaming Lan; Gary Wong

doi:10.3389/fcimb.2023.1174030

Advances and perspectives in the development of vaccines against highly pathogenic bunyaviruses

Front Cell Infect Microbiol. 2023 May 18:13:1174030. doi: 10.3389/fcimb.2023.1174030. eCollection 2023.

Authors

Tong Chen^{1

2}, Zhe Ding^{1

2}, Jiaming Lan¹, Gary Wong¹

Affiliations

¹ Viral Hemorrhagic Fevers Research Unit, Chinese Academy of Sciences (CAS) Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences (CAS), Shanghai, China.
² University of Chinese Academy of Sciences, Beijing, China.

Abstract

Increased human activities around the globe and the rapid development of once rural regions have increased the probability of contact between humans and wild animals. A majority of bunyaviruses are of zoonotic origin, and outbreaks may result in the substantial loss of lives, economy contraction, and social instability. Many bunyaviruses require manipulation in the highest levels of biocontainment, such as Biosafety Level 4 (BSL-4) laboratories, and the scarcity of this resource has limited the development speed of vaccines for these pathogens. Meanwhile, new technologies have been created, and used to innovate vaccines, like the mRNA vaccine platform and bioinformatics-based antigen design. Here, we summarize current vaccine developments for three different bunyaviruses requiring work in the highest levels of biocontainment: Crimean-Congo Hemorrhagic Fever Virus (CCHFV), Rift Valley Fever Virus (RVFV), and Hantaan virus (HTNV), and provide perspectives and potential future directions that can be further explored to advance specific vaccines for humans and livestock.

Keywords: Crimean-Congo Hemorrhagic Fever Virus; Hantaan virus; Rift Valley Fever Virus; bunyaviruses; vaccines.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Hemorrhagic Fever Virus, Crimean-Congo*
Hemorrhagic Fever, Crimean*
Humans
Rift Valley fever virus* / genetics
Vaccines*

Substances

Vaccines

Grants and funding

This study was supported by the Ministry of Science and Technology of China (Grant No. 2021YFC0863400, 2022YFE0114700); and G4 funding from Institut Pasteur, Fondation Merieux, and Chinese Academy of Sciences to GW; and the International Affairs Department of the Institut Pasteur of Paris.